The Oral Mucositis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 3 and 6 respectively.
Pune, India, 18th August 2017: WiseGuyReports announced addition of new report, titled “Oral Mucositis - Pipeline Review, H2 2017
Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation.
Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.
GET SAMPLE REPORT @ www.wiseguyreports.com/sample-requ…ne-review-h2-2017
Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Oral Mucositis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Oral Mucositis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Oral Mucositis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Oral Mucositis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Gastrointestinal)
Reasons to access
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Content: Key Points
Table of Contents 2
List of Tables 3
List of Figures 3
Oral Mucositis - Overview 6
Oral Mucositis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 12
Oral Mucositis - Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Oral Mucositis - Companies Involved in Therapeutics Development 21
Clevexel Pharma SAS 21
Colby Pharmaceutical Company 21
Galera Therapeutics Inc 22
Humanetics Corp 22
Innovation Pharmaceuticals Inc 23
Onxeo SA 23
Oragenics Inc 24
Otsuka Holdings Co Ltd 24
Soligenix Inc 25
Spectrum Pharmaceuticals Inc 25
Spherium Biomed SL 26
Oral Mucositis - Drug Profiles 27
AG-013 - Drug Profile 27
BCD-600 - Drug Profile 30
BIO-300 - Drug Profile 31
brilacidin tetrahydrochloride - Drug Profile 34
clonidine hydrochloride ER - Drug Profile 46
CVXL-0095 - Drug Profile 50
dusquetide - Drug Profile 51
EC-18 - Drug Profile 58
GC-4419 - Drug Profile 60
Gene Therapy for Oral Mucositis - Drug Profile 63
ACCESS REPORT @ www.wiseguyreports.com/reports/177…ne-review-h2-2017
Category: Market Research Publishers and RetailersCompany profile: Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs. Our Market Research Reports and Consulting Services ...
For more information: